On Tuesday, Processa Pharmaceuticals Inc (NASDAQ: PCSA) was -7.77% drop from the session before settling in for the closing price of $0.26. A 52-week range for PCSA has been $0.15 – $1.50.
During the last 5-year period, the sales growth of Healthcare Sector giant was 22.65%. When this article was written, the company’s average yearly earnings per share was at 89.15%. With a float of $49.24 million, this company’s outstanding shares have now reached $52.86 million.
Processa Pharmaceuticals Inc (PCSA) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Processa Pharmaceuticals Inc stocks. The insider ownership of Processa Pharmaceuticals Inc is 13.07%, while institutional ownership is 3.14%. The most recent insider transaction that took place on Jan 27 ’25, was worth 9,889. In this transaction Director of this company bought 12,400 shares at a rate of $0.80, taking the stock ownership to the 12,400 shares. Before that another transaction happened on Jan 27 ’25, when Company’s Chief Executive Officer bought 87,200 for $0.80, making the entire transaction worth $69,542. This insider now owns 87,200 shares in total.
Processa Pharmaceuticals Inc (PCSA) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.74 earnings per share (EPS) during the time that was better than consensus figure (set at -0.92) by 0.18.
According to the Wall Street analysts, stocks earnings will be around 89.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 62.14% during the next five years compared to 22.65% growth over the previous five years of trading.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Trading Performance Indicators
You can see what Processa Pharmaceuticals Inc (PCSA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.36, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.20 in one year’s time.
Technical Analysis of Processa Pharmaceuticals Inc (PCSA)
Looking closely at Processa Pharmaceuticals Inc (NASDAQ: PCSA), its last 5-days average volume was 1.47 million, which is a drop from its year-to-date volume of 8.96 million. As of the previous 9 days, the stock’s Stochastic %D was 10.47%.
During the past 100 days, Processa Pharmaceuticals Inc’s (PCSA) raw stochastic average was set at 20.57%, which indicates a significant increase from 6.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0322 in the past 14 days, which was higher than the 0.0310 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2972, while its 200-day Moving Average is $0.2981. However, in the short run, Processa Pharmaceuticals Inc’s stock first resistance to watch stands at $0.2625. Second resistance stands at $0.2827. The third major resistance level sits at $0.2965. If the price goes on to break the first support level at $0.2285, it is likely to go to the next support level at $0.2147. Should the price break the second support level, the third support level stands at $0.1945.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Key Stats
There are 56,644K outstanding shares of the company, which has a market capitalization of 13.71 million. As of now, sales total 0 K while income totals -11,850 K. Its latest quarter income was 0 K while its last quarter net income were -3,440 K.
